Cevimeline Alternative Sjogren — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateConnective Tissue DiseaseCevimeline Alternative SjogrenSCE Rheumatology

A 50-year-old woman with primary Sjögren disease has troublesome xerostomia without extraglandular organ involvement. A trial of pilocarpine was stopped because of intolerable sweating and flushing. In routine UK practice, which is the most appropriate next management strategy for her oral dryness?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Use saliva substitutes or stimulants with preventive dental care

The correct answer is D. UK BSR guidance for Sjögren disease emphasises symptom management by conserving, replacing and stimulating secretions, alongside prevention of oral damage. Following intolerance of pilocarpine, management of uncomplicated xerostomia should include saliva substitutes and/or non-drug saliva stimulation, with regular dental surveillance and preventive dental care. Cevimeline is a muscarinic agonist with evidence of efficacy internationally, but it is not a routinely available licensed systemic alternative in UK practice; therefore it is not the best answer for a UK SCE item. Rituximab and intravenous immunoglobulin may have roles in selected systemic disease manifestations, not isolated oral dryness. Reassurance alone fails to address symptoms and the increased risk of dental complications.

Reference: Price EJ et al. British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology (Oxford), 2025; management principles for conserving, replacing and stimulating secretions. https://pubmed.ncbi.nlm.nih.gov/11726216/